论文部分内容阅读
巨噬细胞移动抑制因子(macrophage migration inhibitory factor,MIF)是一种前炎症细胞因子,具有生长因子和多种酶活性的特点。近年研究表明:MIF参与了体内血糖调节和冠心病的病理生理过程。在1型糖尿病动物模型中,用抗MIF治疗策略可减轻糖尿病高血糖及胰岛炎的程度。2型糖尿病患者血浆MIF水平升高,且MIF的单核苷酸多态性C等位基因rs1007888与女性患者的2型糖尿病发病率密切相关。MIF还参与冠心病动脉粥样硬化斑块的形成,影响斑块稳定性,选用MIF抗体、敲除MIF基因或影响MIF基因表达均可望成为治疗冠状动脉粥样硬化的有益探索。MIF基因-173G/C位点多样性与冠心病易感性有关,血MIF水平在不同类型冠心病中有差异。因此,MIF如何参与糖尿病性冠心病的病理生理过程,仍有待进一步证明。
Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that has the characteristics of growth factors and various enzyme activities. Recent studies show that: MIF involved in the regulation of blood glucose and coronary heart disease pathophysiology. In an animal model of type 1 diabetes, anti-MIF treatment strategies reduce the severity of diabetic hyperglycemia and insulitis. Plasma MIF levels are elevated in patients with type 2 diabetes mellitus, and the SNP rs1007888 of MIF SNP is closely related to the incidence of type 2 diabetes in women. MIF also participates in the formation of atherosclerotic plaque in coronary heart disease and affects the stability of plaque. MIF antibody knockdown, MIF gene knockdown or MIF gene expression are all expected to be useful exploration for the treatment of coronary atherosclerosis. MIF gene -173G / C locus diversity and coronary heart disease susceptibility, blood levels of MIF in different types of coronary heart disease are different. Therefore, how to participate in the pathophysiology of diabetic coronary heart disease remains to be further proved.